
-
Rhythm Pharmaceuticals NasdaqGM:RYTM Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Location: 222 Berkeley Street, Boston, MA, 02116, United States | Website: https://rhythmtx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.88B
Cash
314.5M
Avg Qtr Burn
-28.37M
Short % of Float
9.84%
Insider Ownership
0.62%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
Approved Quarterly sales | ||
IMCIVREE™ (Setmelanotide) Details Rare genetic disease, Bardet-Biedl syndrome | Approved Quarterly sales | |
Approved Quarterly sales | ||
IMCIVREE™ (Setmelanotide) Details Acquired Hypothalamic Obesity (HO) | sNDA Submission | |
IMCIVREE™ (Setmelanotide) Details Rare genetic disease | NDA FDA meeting | |
IMCIVREE™ (Setmelanotide) Details Congenital Hypothalamic Obesity (HO) | Phase 3 Data readout | |
IMCIVREE™ (Setmelanotide) Details Genetically [POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1] caused MC4R pathway diseases | Phase 3 Data readout | |
LB54640 Details Obesity | Phase 2 Data readout | |
IMCIVREE™ (Setmelanotide) Details Prader-Willi syndrome (PWS) | Phase 2 Data readout | |
Bivamelagon Details Acquired Hypothalamic Obesity (HO) | Phase 2 Data readout | |
RM-718 Details Acquired hypothalamic obesity (HO) | Phase 1 Data readout |